Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.
The therapeutic benefit from phosphorothioate oligodeoxynucleotides (PS ODN) containing immune stimulatory sequences (ISS) has been demonstrated in animal models of cancer and infection. In particular, when CpG-containing PS ODN are administered to mice, activation of macrophages and dendritic, NK, T, and B cells occurs, resulting in the release of an array of cytokines, including interleukin-12 (IL-12), interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha). We have previously described stabilized antisense-lipid particles (SALP) for the i.v. administration of antisense ODN [Biochim Biophys Acta (2001) 1510:152--166]. Given the propensity for SALP to target macrophages in vivo it was of interest to determine whether they could enhance the potency of CpG ODN to induce an immune response. In this report we show that when CpG-containing SALP are administered intravenously to ICR mice the plasma concentrations of IL-12, IFN-gamma, IL-6, monocyte chemoattractant protein-1, and TNF-alpha are greatly increased compared with the same dose of free ODN. The pattern of cytokine induction indicates that the immune response is T helper cell type 1-biased, similar to that observed for PS CpG ODN ISS in general. Furthermore, when phosphodiester (PO) ODN is substituted for PS ODN in the SALP formulation cytokine induction is even greater at the early time points, in marked contrast to free PO ODN, which is inactive. These results demonstrate that the immunogenicity of ISS is not only enhanced by encapsulation in lipid particles, which more closely mimic the way ISS DNA would normally be presented to antigen presenting cells by pathogens in vivo, but also SALP enable unmodified PO CpG ODN to be used as immune stimulants.
Mui
B
B
Inex Pharmaceuticals Corporation, Burnaby, British Columbia, Canada. bmui@inexpharm.com
Raney
S G
SG
Semple
S C
SC
Hope
M J
MJ
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D018899:CpG Islands; D016207:Cytokines / Q000097:blood; D004337:Drug Carriers; D004339:Drug Compounding; D007275:Injections, Intravenous; D008055:Lipids; D008081:Liposomes; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008813:Mice, Inbred ICR; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D016207:Cytokines; D004337:Drug Carriers; D008055:Lipids; D008081:Liposomes; D016376:Oligonucleotides, Antisense